Preexisting Insulin Autoantibodies Predict Efficacy of Otelixizumab in Preserving Residual β-Cell Function in Recent-Onset Type 1 Diabetes | Zendy

Simke Demeester | Zendy; Bart Keymeulen | Zendy; Leonard Kaufman | Zendy; Annelien Van Dalem | Zendy; Eric V. Balti | Zendy; Ursule Van de Velde | Zendy; Patrick Goubert | Zendy; Katrijn Verhaeghen | Zendy; Howard W. Davidson | Zendy; Janet M. Wenzlau | Zendy; Ilse Weets | Zendy; Daniël Pipeleers | Zendy; Frans Gorus | Zendy

Open Access

Preexisting Insulin Autoantibodies Predict Efficacy of Otelixizumab in Preserving Residual β-Cell Function in Recent-Onset Type 1 Diabetes

Author(s) -

Simke Demeester,

Bart Keymeulen,

Leonard Kaufman,

Annelien Van Dalem,

Eric V. Balti,

Ursule Van de Velde,

Patrick Goubert,

Katrijn Verhaeghen,

Howard W. Davidson,

Janet M. Wenzlau,

Ilse Weets,

Daniël Pipeleers,

Frans Gorus

Publication year - 2015

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc14-1575

Subject(s) - medicine , autoantibody , insulin , diabetes mellitus , placebo , type 1 diabetes , randomization , area under the curve , endocrinology , c peptide , type 2 diabetes , randomized controlled trial , gastroenterology , antibody , immunology , pathology , alternative medicine

Immune intervention trials in recent-onset type 1 diabetes would benefit from biomarkers associated with good therapeutic response. In the previously reported randomized placebo-controlled anti-CD3 study (otelixizumab; GlaxoSmithKline), we tested the hypothesis that specific diabetes autoantibodies might serve this purpose.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research